Company intelligence / Profile preview

Sachi Bio

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Four drug candidates in preclinical development for Parkinson's, inflammatory bowel disease, an undisclosed neuroimmune disease, and one candidate designed to counteract radiation exposure. In a NASA space medicine project, identified 17 target genes in 6 weeks and demonstrated ability to turn proteins on and off as desired in mice without needing a lipid to bind and deliver the treatment and without creating toxic concentrations in the liver or other key organs.

Therapeutic areas: GastroenterologyNeurologyOther
Modalities: RNA therapeuticsnucleic acid molecules
Industry: Biotech

Partnerships

NASA (space medicine project)SpaceX (CRS-31 mission)

Beyond the preview

Go deeper on Sachi Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sachi Bio.

Explore the full profile